Endostatin gene therapy stimulates upregulation of ICAM-1 and VCAM-1 in a metastatic renal cell carcinoma model

被引:14
作者
Chaves, K. C. B. [1 ,2 ]
Peron, J. P. S. [3 ]
Chammas, R. [4 ]
Turaca, L. T. [5 ]
Pesquero, J. B. [5 ]
Braga, M. S. [1 ,2 ]
Foguer, K. [1 ,2 ]
Schor, N. [2 ]
Bellini, M. H. [1 ,2 ]
机构
[1] Univ Fed Sao Paulo, IPEN CNEN, Dept Biotechnol, BR-05508000 Sao Paulo, Brazil
[2] Univ Fed Sao Paulo, Div Nephrol, Dept Med, BR-05508000 Sao Paulo, Brazil
[3] Univ Sao Paulo, Dept Immunol, ICB 4, Sao Paulo, Brazil
[4] Univ Sao Paulo, Dept Radiol, Sao Paulo, Brazil
[5] Univ Fed Sao Paulo, Dept Biophys, BR-05508000 Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
RCC; endostatin; orthotopic metastatic model; ICAM-1; VCAM-1; ENDOTHELIAL-CELLS; ADHESION MOLECULE-1; PROGNOSTIC-FACTORS; CANCER; EXPRESSION; SURVIVAL; ANERGY;
D O I
10.1038/cgt.2012.32
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
One of the greatest challenges in urological oncology is renal cell carcinoma (RCC), which is the third leading cause of death in genitourinary cancers. RCCs are highly vascularized and respond positively to antiangiogenic therapy. Endostatin (ES) is a fragment of collagen XVIII that possesses antiangiogenic activity. In this study, we examined the potential of ES-based antiangiogenic therapy to activate tumor-associated endothelial cells in metastatic RCC (mRCC). Balb/c-bearing Renca cells were treated with NIH/3T3-LendSN or, as a control, with NIH/3T3-LXSN cells. The T-cell subsets and lymphocyte populations of tumors, mediastinal lymph nodes and the spleen were assessed by flow cytometry. The expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) was assessed by real-time PCR, flow cytometry and immunohistochemistry analysis. ES gene therapy led to an increase in the percentage of infiltrating CD4-interferon (IFN)-gamma cells (P<0.05), CD8-IFN-gamma cells (P<0.01) and CD49b-tumor necrosis factor-alpha cells (P<0.01). In addition, ES therapy caused an increase at the mRNA level of ICAM-1 (1.4-fold; P<0.01) and VCAM-1 (1.5-fold) (control vs treated group; P<0.001). Through flow cytometry, we found a significant increase in the CD34/ICAM-1 cells (8.1-fold; P<0.001) and CD34/VCAM-1 cells (1.6-fold; P<0.05). ES gene therapy induced a significant increase in both T CD4 and CD8 cells in the lymph nodes and the spleen, suggesting that ES therapy may facilitate cell survival or clonal expansion. CD49b cells were also present in increased quantities in all of these organs. In this study, we demonstrate an antitumor inflammatory effect of ES in an mRCC model, and this effect is mediated by an increase in ICAM-1 and VCAM-1 expression in tumor-associated endothelial cells.
引用
收藏
页码:558 / 565
页数:8
相关论文
共 42 条
[1]   Interleukin-2: Clinical applications [J].
Atkins, MB .
SEMINARS IN ONCOLOGY, 2002, 29 (03) :12-17
[2]   Simultaneous Infiltration of Polyfunctional Effector and Suppressor T Cells into Renal Cell Carcinomas [J].
Attig, Sebastian ;
Hennenlotter, Joerg ;
Pawelec, Graham ;
Klein, Gerd ;
Koch, Sven D. ;
Pircher, Hanspeter ;
Feyerabend, Susan ;
Wernet, Dorothee ;
Stenzl, Arnulf ;
Rammensee, Hans-Georg ;
Gouttefangeas, Cecile .
CANCER RESEARCH, 2009, 69 (21) :8412-8419
[3]   Tumor-Endothelium Cross Talk Blocks Recruitment of Neutrophils to Endothelial Cells: A Novel Mechanism of Endothelial Cell Anergy [J].
Blaheta, Roman A. ;
Powerski, Maciej ;
Hudak, Lukasz ;
Juengel, Eva ;
Jonas, Dietger ;
von Knethen, Andreas ;
Doerr, Hans W. ;
Cinatl, Jindrich .
NEOPLASIA, 2009, 11 (10) :1054-1063
[4]   Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL-mutant renal carcinoma cells [J].
Chintalapudi, Mastan R. ;
Markiewicz, Margaret ;
Kose, Nurgun ;
Dammai, Vincent ;
Champion, Kristen J. ;
Hoda, Rana S. ;
Trojanowska, Maria ;
Hsu, Tien .
CARCINOGENESIS, 2008, 29 (04) :696-703
[5]   Endothelial Cells as Key Determinants of the Tumor Microenvironment: Interaction With Tumor Cells, Extracellular Matrix and Immune Killer Cells [J].
Chouaib, Salem ;
Kieda, Claudine ;
Benlalam, Houssem ;
Noman, Muhammad Zaeem ;
Mami-Chouaib, Fathia ;
Ruegg, Curzio .
CRITICAL REVIEWS IN IMMUNOLOGY, 2010, 30 (06) :529-545
[6]   Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies [J].
Chowdhury, Simon ;
Larkin, James M. G. ;
Gore, Martin E. .
EUROPEAN JOURNAL OF CANCER, 2008, 44 (15) :2152-2161
[7]  
Cichy MC, 2009, BRAZ J MED BIOL RES, V42, P1150, DOI 10.1590/S0100-879X2009001200005
[8]   Anti-tumor effect of endostatin mediated by retroviral gene transfer in mice bearing renal cell carcinoma [J].
Coutinho, Enia Lucia ;
Andrade, Luciana Nogueira de Sousa ;
Chammas, Roger ;
Morganti, Ligia ;
Schor, Nestor ;
Bellini, Maria Helena .
FASEB JOURNAL, 2007, 21 (12) :3153-3161
[9]   Endostatin- and interleukin-2-expressing retroviral bicistronic vector for gene therapy of metastatic renal cell carcinoma [J].
de Goes Rocha, Flavia Gomes ;
Calvo, Fernanda B. ;
Chaves, Karen C. ;
Peron, Jean P. S. ;
Marques, Rodolfo F. ;
de Borba, Tania R. ;
Braga, Marina S. ;
Pereira, Cleide B. ;
Vicente, Elisabete J. ;
Chammas, Roger ;
Schor, Nestor ;
Bellini, Maria H. .
JOURNAL OF GENE MEDICINE, 2011, 13 (03) :148-157
[10]   Erythrocyte Protoporphyrin Fluorescence as a Biomarker for Monitoring Antiangiogenic Cancer Therapy [J].
de Goes Rocha, Flavia Gomes ;
Barbosa Chaves, Karen Cristina ;
Gomes, Cinthia Zanini ;
Campanharo, Camila Barricheli ;
Courrol, Lilia Coronato ;
Schor, Nestor ;
Bellini, Maria Helena .
JOURNAL OF FLUORESCENCE, 2010, 20 (06) :1225-1231